An Introduction to Cardiovascular Risk
Despite substantial treatment advances, cardiovascular diseases (CVDs) remain the leading cause of death in the world. Recent research has revealed that nearly seven in ten cases of CVD can be explained by modifiable risk factors: such as high blood pressure, abdominal obesity, low education, smoking, dyslipidaemia, poor diet, strength and physical activity, diabetes, depression, and air pollution. Diagnosis and management of these risk factors are essential to preventing premature deaths due to CVD. However, there remains a significant risk of cardiovascular events despite optimal risk factor management. Other less understood, potentially modifiable risk factors include inflammatory, pro-thrombotic and metabolic pathways, and warrant further study.
Browse our gallery of video highlights and short articles from the conference hub, providing the latest expert insights from major conferences and peer-reviewed articles from the journal portfolio.
Cardiovascular Risk Content
Statin-related Muscle Toxicity: An Evidence-based Review
touchREVIEWS in Endocrinology. 2022;18(2):89-95 DOI: https://doi.org/10.17925/EE.2022.18.2.89
In the early 1970s, the discovery of statin by Dr Akira Endo changed the fate of cardiovascular disease prevention and the treatment of atherosclerosis. It was during this period that the rate-limiting step in cholesterol biosynthesis was revealed, and the enzyme hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase became the target for many pharmaceutical products. Brought up in […]
Multidisciplinary insights on the role of GLP-1 RAs in the modern management of stroke in patients with T2D
A multidisciplinary team and a patient discuss GLP-1 RAs and their role in stroke prevention in patients with T2D.
- Describe the burden of stroke and risk factors for stroke in patients with T2D
- Evaluate the latest data for GLP-1 RAs in the context of stroke management and prevention
- Interpret current treatment guidelines for T2D in the context of stroke management and prevention and apply it to clinical practice
APOC3 Interference for Familial Chylomicronaemia Syndrome
touchREVIEWS in Endocrinology. 2022;18(2):82-3 DOI: https://doi.org/10.17925/EE.2022.18.2.82
Chylomicronaemia refers to the pathological presence of large, circulating, intestinally derived chylomicrons.1 Clinical features of chylomicronaemia syndrome include lipaemic plasma, lipaemia retinalis, eruptive xanthomas, hepatosplenomegaly, neurological symptoms such as mental fog and mood changes and, most importantly, increased risk of acute pancreatitis.1,2 When smaller atherogenic triglyceride (TG)-rich lipoproteins are concomitantly elevated, the risk of myocardial infarction […]
Addressing cardiorenal outcomes in CKD and T2D: What are the key considerations for daily practice?
Watch experts in endocrinology and in primary care discuss key considerations for addressing cardiorenal outcomes in patients with CKD/T2D
- Identify the epidemiological and pathophysiological drivers behind the progression of CKD
- Recognize the specific renal and cardiovascular risks associated with CKD and T2D and the therapies available to address them
- Apply the latest clinical guidelines to treating patients with CKD and T2D in daily practice
Peter Rossing, EASD 2022: The relationship between cardiovascular and renal risks in diabetes
Diabetes increases the risk of cardiovascular (CV) and renal disease (CVRD). These become major causes of mortality in individuals with diabetes. In this touchENDOCRINOLOGY interview, Prof. Peter Rossing (University of Copenhagen, Copenhagen, Denmark) discusses the relationship between cardiovascular and renal risks in diabetes The abstract entitled: ‘Effect of semaglutide on MACE by baseline kidney function in participants […]
Peter Rossing, EASD 2022: The effect of semaglutide on risk of MACE by baseline kidney function: SUSTAIN 6 and PIONEER 6 post hoc analysis
SUSTAIN 6 and PIONEER 6 investigated the effects of semaglutide versus placebo on major adverse cardiovascular events (MACE). The current post hoc analysis investigated the association between baseline kidney function and risk of MACE, and the effect of semaglutide on risk of MACE by baseline kidney function. In this touchENDOCRINOLOGY interview, Prof. Peter Rossing (University […]
Hertzel Gerstein, ADA 2022: The ELIXA biomarker study, protein biomarkers to identify cardiovascular outcomes in patients with type 2 diabetes and acute coronary syndrome
The ELIXA biomarker study evaluated protein biomarkers as clinical risk factors to identify people with type 2 diabetes and acute coronary syndrome who are at highest risk for cardiovascular (CV) outcomes and death. Professor Hertzel Gerstein (McMaster University, Hamilton, ON, Canada) discusses the outcomes of the ELIXA biomarker study and the implications of the findings […]
Hertzel Gerstein, ADA 2022: Risk factors for cardiovascular disease in patients with type 2 diabetes
The clinical risk factors for cardiovascular disease in patients with type 2 diabetes and the link between the two is discussed by Professor Hertzel Gerstein (McMaster University, Hamilton, ON, Canada). Professor Hertzel Gerstein presented an abstract entitled ‘Cardiovascular Outcomes in People with Type 2 Diabetes and Acute Coronary Syndrome—The ELIXA Biomarker Study‘ at the 82nd […]
Integrating GLP-1 RAs into T2D management: A unified approach, from PCP to patient
Watch specialists within an MDT, plus a patient, discuss the role of GLP-1 RAs in the management of T2D.
- Evaluate the data supporting the use of GLP-1 RAs for treatment of T2D and apply them to practical considerations associated with GLP-1 RA use
- Manage potential side effects of GLP-1 RAs, including GI symptoms, and discuss self-management with patients
- Recognize the role of GLP-1 RAs in the T2D management pathway and apply this knowledge to clinical practice
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!